In a session at ECTRIMS 2021, researchers discussed the role of biosensors in the clinical care of patients with multiple sclerosis (MS) and highlighted current challenges.
“The COVID-19 pandemic accelerated the need for at-home biosensing,” said Professor Tanuja Chitnis of Harvard University in Boston, Massachusetts, USA.
“Approximately 50% to 90% of our patients during the peak of the pandemic were being seen by telehealth. This made it difficult to assess neurological measures and disability. So we need a proxy to assess clinical status and monitor disease progression.”